Novartis Ag

Sandoz Gmbh

Novartis Tiergesundheit Ag

Novartis Pharma Gmbh

Peter C Hiestand

Murat Acemoglu

David Bodmer

Salvatore Cammisuli

Christian Schnell

Siegfried Bantle

Fritz Nimmerfall

Georg Stoll

Mahavir Prashad

Yugang Liu

Reto Naef

Pietro Bollinger

Bernhard Riss

Paul William Glue

Michael Strasser

Janet Dawson King

Lukas Oberer

Hans-Ulrich Naegeli

Hans-Jorg Roth

Friedrich Schuerch

Vincent Schmid

Jonathan King

Carolyn An Foster

The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.

S1P receptor modulators for treating relasping-remitting multiple sclerosis

The present invention relates to the use of the S1P receptor modulator 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, administered at a daily dosage of 0.5 mg, for inhibiting or treating neo-angiogenesis associated with multiple sclerosis.

S1P receptor modulators for treating multiple sclerosis

The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment of pain in animals and humans. More particularly, the present invention relates to pharmaceutical, preferably veterinary compositions and methods for reducing inflammation and pain associated with acute inflammation of body parts, particularly joints, due to injury or due to arthritic conditions or other disease conditions.

Organic compounds

This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF&agr;, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.

Polymeric matrices and their uses in pharmaceutical compositions

This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF.alpha., e.g., certain autoimmune and inflammatory conditions, as well as septic shock.

Tetracyclic triterpenes

Novel bis- and poly-disulfides having immunostimulant activity

Growing community of inventors

Allschwil, Switzerland

Peter C Hiestand